MedTrace Logo

Mirvaso in Use Study

NCT02249065 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2022-08-01

Study results available
· View outcomes & findings →

Summary

This study is designed to:

1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel
2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment
3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.

Conditions

  • Rosacea

Interventions

DRUG

Brimonidine

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Jeffrey Sugarman, MD · Redwood Dermatology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249065 on ClinicalTrials.gov